A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)

Joensuu Heikki; Fraser Judith; Wildiers Hans; Huovinen Riikka; Auvinen Paivi; Utriainen Meri; Nyandoto Paul; Villman Kenneth K.; Halonen Paivi; Granstam-Bjorneklett Helena; Lundgren Lotta; Yachnin Jeffrey; Turpeenniemi-Hujanen Taina; Ritchie Diana; Huttunen Teppo; Neven Patric; Canney Peter; Harvey Vernon J.; Kellokumpu-Lehtinen Pirkko-Liisa; Lindman Henrik

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)

作者：Joensuu Heikki; Fraser Judith; Wildiers Hans; Huovinen Riikka; Auvinen Paivi; Utriainen Meri; Nyandoto Paul; Villman Kenneth K.; Halonen Paivi; Granstam-Bjorneklett Helena; Lundgren Lotta; Yachnin Jeffrey; Turpeenniemi-Hujanen Taina; Ritchie Diana; Huttunen Teppo; Neven Patric; Canney Peter; Harvey Vernon J.; Kellokumpu-Lehtinen Pirkko-Liisa; Lindman Henrik

来源：San Antonio Breast Cancer Symposium, 2017-12-05 to 2017-12-09.

出版日期2018-2

收藏分享被引浏览

更新时间：2018-11-23 06:38

相似论文
引用论文
参考文献

A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)

产品服务

站内浏览

服务支持

联系方式

科研之友